Tau pathology spreads through synaptically connected brain regions in Alzheimer disease following a stereotyped anatomical pattern. Mechanisms of trans-synaptic tau propagation via extracellular vesicles, tunneling nanotubes, and synaptic release need clarification.
Tau is selectively sorted into intraluminal vesicles of multivesicular bodies via ALIX/syntenin-1 ESCRT machinery before exosome release. ALIX knockout or syntenin-1 inhibition would prevent exosomal tau propagation, but exosome specificity and ALIX pleiotropy complicate interpretation.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%3 supporting / 4 opposing
✓For(3)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
3
MECH 4CLIN 0GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Tau is packaged into exosomes via an ALIX-dependen…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-22 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic and Therapeutic Hypotheses: Trans-synaptic Tau Propagation in Alzheimer's Disease
Hypothesis 1: Targeting Synaptic Vesicle Release Machinery to Block Tau Exocytosis
Mechanism: Neuronal activity-dependent tau release occurs via synaptic vesicle fusion, involving SNARE complex assembly (SNAP-25, VAMP2, syntaxin-1) and synaptotagmin-1 calcium sensing. Inhibition of vesicle release would reduce trans-synaptic tau efflux.
Molecular target confusion: The hypothesis conflates SNAP-23 with SNAP-25. SNAP-23 is predominantly expressed in non-neuronal cells and glial cells, whereas SNAP-25 is the canonical presynaptic SNARE. This represents a significant mechanistic error that undermines the experimental design. The cited Brilliant et al. (2021) study using SNAP-23 knockdown in neurons may reflect off-target effects or non-vesicular pathways.
Correlation vs. causation: Yamada e
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: Trans-Synaptic Tau Propagation Mechanisms in Alzheimer's Disease
Executive Summary
Following rigorous critical evaluation, three hypotheses merit substantive feasibility assessment: H3 (HSPG blockade), H6 (TREM2 activation), and H1 (SNARE inhibition). The remaining four hypotheses either possess fatal mechanistic flaws or insufficient evidentiary foundation to justify near-term therapeutic development investment. This assessment covers druggability, biomarkers and model systems, clinical-development constraints, safety considerations, and realistic ti
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation", "description": "TREM2 agonism promotes microglial clearance of extracellular tau aggregates. Loss-of-function R47H variant impairs tau clearance and enhances spreading. Agonistic antibodies (AL002) are in clinical development, offering highest feasibility among surviving hypotheses with human genetics support and established regulatory pathway.", "target_gene": "TREM2", "dimension_scores": { "evidence_strength": 0.82, "novelty": 0.58,